The present status and future prospects of peptide-based cancer vaccines - PubMed (original) (raw)
Review
doi: 10.1093/intimm/dxw027. Epub 2016 May 28.
Affiliations
- PMID: 27235694
- DOI: 10.1093/intimm/dxw027
Review
The present status and future prospects of peptide-based cancer vaccines
Masatoshi Hirayama et al. Int Immunol. 2016 Jul.
Abstract
Tumor cells commonly express several antigens, such as tumor-associated antigens (TAAs) or mutation-derived antigens (neoantigens), that can be regarded as foreign antigens and elicit anti-tumor immune responses in cancer patients. Various TAAs or neoantigens expressed in cancer cells have been identified and utilized as targets for cancer vaccines. One approach to elicit tumor-specific immune responses is termed peptide-based cancer vaccination; it involves administrating TAAs or neoantigen-derived peptide for treatment of cancers. There have been several forms of peptide-based cancer vaccines depending on which effector cells, such as CTLs or CD4(+) T-helper cells, are targeted to be activated. Many phase I and II clinical trials of peptide-based cancer vaccines using TAA-derived CTL epitopes, T-helper cell epitopes or dendritic cells loaded with TAA-derived peptides for various malignant tumors have been conducted and provide clinical benefits in a small fraction of patients. Nowadays, to improve the efficiency of peptide-based cancer vaccines, combination immunotherapy of peptide-based cancer vaccines with the immune-checkpoint blockade therapies using mAbs specific for CTLA-4, programmed cell death 1 (PD-1), or PD-1 ligand 1 (PD-L1) have been developed for clinical application. Furthermore, along with the recent technological progress in genetic and bioinformatic analysis, it has become easier to identify neoantigens from individual cancer patients. It is expected that peptide-based cancer vaccines targeting neoantigens as a personalized cancer immunotherapy will be developed.
Keywords: neoantigen; peptide-based cancer vaccine; tumor-associated antigen; tumor-reactive T cell.
© The Japanese Society for Immunology. 2016. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
- Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
Furness AJ, Quezada SA, Peggs KS. Furness AJ, et al. Immunotherapy. 2016 Jun;8(7):763-6. doi: 10.2217/imt-2016-0064. Immunotherapy. 2016. PMID: 27349975 No abstract available. - Introduction: Cancer Immunology Special Issue-Immunotherapy.
Kawakami Y. Kawakami Y. Int Immunol. 2016 Jul;28(7):317. doi: 10.1093/intimm/dxw028. Epub 2016 Jun 15. Int Immunol. 2016. PMID: 27313100 No abstract available. - The role of neoantigens in response to immune checkpoint blockade.
Riaz N, Morris L, Havel JJ, Makarov V, Desrichard A, Chan TA. Riaz N, et al. Int Immunol. 2016 Aug;28(8):411-9. doi: 10.1093/intimm/dxw019. Epub 2016 Apr 5. Int Immunol. 2016. PMID: 27048318 Free PMC article. Review. - Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
Pan RY, Chung WH, Chu MT, Chen SJ, Chen HC, Zheng L, Hung SI. Pan RY, et al. J Immunol Res. 2018 Dec 19;2018:4325874. doi: 10.1155/2018/4325874. eCollection 2018. J Immunol Res. 2018. PMID: 30662919 Free PMC article. Review. - Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR, Dong JZ. Aldous AR, et al. Bioorg Med Chem. 2018 Jun 1;26(10):2842-2849. doi: 10.1016/j.bmc.2017.10.021. Epub 2017 Oct 19. Bioorg Med Chem. 2018. PMID: 29111369 Review.
Cited by
- Tuning the fluidity and protein corona of ultrasound-responsive liposomal nanovaccines to program T cell immunity in mice.
He J, Wang C, Fang X, Li J, Shen X, Zhang J, Peng C, Li H, Li S, Karp JM, Kuai R. He J, et al. Nat Commun. 2024 Sep 16;15(1):8121. doi: 10.1038/s41467-024-52104-z. Nat Commun. 2024. PMID: 39284814 Free PMC article. - Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy.
Joshi DC, Sharma A, Prasad S, Singh K, Kumar M, Sherawat K, Tuli HS, Gupta M. Joshi DC, et al. Discov Oncol. 2024 Aug 11;15(1):342. doi: 10.1007/s12672-024-01195-7. Discov Oncol. 2024. PMID: 39127974 Free PMC article. Review. - PLGA-PEI nanoparticle covered with poly(I:C) for personalised cancer immunotherapy.
Gonzalez-Melero L, Santos-Vizcaino E, Varela-Calvino R, Gomez-Tourino I, Asumendi A, Boyano MD, Igartua M, Hernandez RM. Gonzalez-Melero L, et al. Drug Deliv Transl Res. 2024 Oct;14(10):2788-2803. doi: 10.1007/s13346-024-01557-2. Epub 2024 Mar 1. Drug Deliv Transl Res. 2024. PMID: 38427275 - In silico Identification of MHC Displayed Tumor Associated Peptides in Ovarian Cancer for Multi-Epitope Vaccine Construct.
Dobhal S, Chauhan K, Kumar S, Shikha S, Jogi MK, Kumar D, Kumar A, Jaiswal VK, Kumar P. Dobhal S, et al. Endocr Metab Immune Disord Drug Targets. 2024;24(12):1401-1413. doi: 10.2174/0118715303169428231205173914. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 38275062 - Oral Administration of Cancer Vaccines: Challenges and Future Perspectives.
Gambirasi M, Safa A, Vruzhaj I, Giacomin A, Sartor F, Toffoli G. Gambirasi M, et al. Vaccines (Basel). 2023 Dec 26;12(1):26. doi: 10.3390/vaccines12010026. Vaccines (Basel). 2023. PMID: 38250839 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials